ArticleFrontiers in immunology2017
The Different Functional Distribution of "Not Effector" T Cells (Treg/Tnull) in Colorectal Cancer.
Article in Frontiers in immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 40 citations in OpenAlex.
- Th1-2 immune balance revisited: refining prognostic immune signatures in colorectal cancer.Journal of gastrointestinal oncology · 2026Article
- Microbiota-Derived Proteins Shape T Cell Responses in Healthy and Colorectal Cancer Subjects.Biomedicines · 2026Article
- Significance of Th1 and Th2 Cell Densities and Th1/Th2 Cytokine Profiles in Colorectal Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025Article
- Gut microbiome and nutritional strategies in gastrointestinal cancers: Clinical implications and therapeutic perspectives.World journal of clinical oncology · 2025Review
- Tumor-Infiltrating Immune Cells in Colorectal Cancer.Neoplasia (New York, N.Y.) · 2025Review
- A comparative study of carbonic anhydrase activity in lymphocytes from colorectal cancer tissues and adjacent healthy counterparts.Journal of enzyme inhibition and medicinal chemistry · 2022Article
- Gut Microbiota and Associated Mucosal Immune Response in Eosinophilic Granulomatosis with Polyangiitis (EGPA).Biomedicines · 2022Article
- Gut mucosal microbiota profiles linked to colorectal cancer recurrence.World journal of gastroenterology · 2022Article
- Article
- Characterization of the "gut microbiota-immunity axis" and microbial lipid metabolites in atrophic and potential celiac disease.Frontiers in microbiology · 2022Article
- Systemic Interleukins' Profile in Early and Advanced Colorectal Cancer.International journal of molecular sciences · 2021Review
- Fecal metabolomic profiles: A comparative study of patients with colorectal cancerWorld journal of gastroenterology · 2021Article
- Ex vivo modelling of PD-1/PD-L1 immune checkpoint blockade under acute, chronic, and exhaustion-like conditions of T-cell stimulation.Scientific reports · 2021Article
- The Regulation of Intestinal Inflammation and Cancer Development by Type 2 Immune Responses.International journal of molecular sciences · 2020Review
- Immune Landscape in Tumor Microenvironment: Implications for Biomarker Development and Immunotherapy.International journal of molecular sciences · 2020Review
- Metabolomics profile in gastrointestinal cancers: Update and future perspectives.World journal of gastroenterology · 2020Review
- Resolving the Paradox of Colon Cancer Through the Integration of Genetics, Immunology, and the Microbiota.Frontiers in immunology · 2020Review
- Significant and Conflicting Correlation of IL-9 WithFrontiers in immunology · 2020Observational
- Evaluation and comparison of short chain fatty acids composition in gut diseases.World journal of gastroenterology · 2019Observational
- Healthy axis: Towards an integrated view of the gut-brain health.World journal of gastroenterology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is the third most common cancer worldwide, ranking as high as the second leading cause of cancer-related deaths in industrialized countries. Consistent with immunosurveillance theory, the immune system is crucial to protect the host from developing tumors, and the major players in tumoral immunity are effector T cells. Anyway, cancer cells develop strategies of immunoevasion influencing the cancer-specific lymphocyte priming, activation, and effector function. Therefore, the T cell subsets that mature during the stages of tumor growth, differently contribute to disease progression and/or regression. In our study, we analyzed the intra-tumoral and peripheral T cell subsets' distribution in 30 patients with CRC, in order to clarify their functional role toward cancer. We found that percentage of infiltrating effector T cells decreased in cancer tissue than in healthy mucosa and that the tumor microenvironment negatively influences the cytolytic activity of T lymphocytes reactive to cancer cells. Moreover, we found that the tumor tissue was infiltrated by a large amount of "not effector" T (neT) cells with a regulatory or an anergic profile, which are unable to kill cancer cells, may be contributing to the CRC promotion. The presence of neT cells was investigated also in the peripheral blood of CRC patients, demonstrating that the peripheral T regulatory cells can inhibit the proliferation of effector T cells, confirming their immunosuppressive properties. Finally, monitoring the changes in circulating neT cells' frequencies after the tumor removal, we confirmed the role of cancer in the modulation of immune system, in particular, in supporting a Tregs-mediated immunosuppression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.